Background: Nocturnal hypoxemia is an important factor underlying the impact of sleep apnea on heart failure. It remains unclear whether nocturnal hypoxemia has a greater prognostic value in acute decompensated heart failure (ADHF) compared with the frequency of sleep apnea.
| INTRODUCTION
Sleep apnea, typically categorized as predominantly obstructive (OSA) or central (CSA), is highly prevalent in both acute decompensated heart failure (ADHF) 1, 2 and chronic stable heart failure. 3, 4 Sleep apnea is responsible for multiple cardiovascular pathophysiological changes in heart failure, such as myocardial ischemia, 5 increased pulmonary arterial pressure, 6 and abnormal cardiac electrophysiological activities, 7, 8 based on complex mechanisms, including nocturnal hypoxemia, increased sympathetic activity, enhanced renin-angiotensinaldosterone system, and chronic inflammation. 9, 10 It has been reported that sleep apnea, generally scored by the apnea-hypopnea index (AHI), might be an independent risk factor of adverse outcomes in heart failure. 1, 2, 11 However, AHI has been questioned as a prognostic predictor of heart failure in some studies. 12, 13 AHI is only a metric reflecting the frequency of apneas and hypopneas during sleep and does not take the lengths of apneas and hypopneas into consideration on its own definition. Therefore, more importance should be attached to detailed characteristics of sleep apnea.
Nocturnal hypoxemia, as a composite consequence of apneas and hypopneas, might better represent the adverse effects of nocturnal respiratory events in heart failure. Gottlieb et al reported that increased hemodynamic stress in heart failure was related to the percentage of time with saturation below 90% (T90%), but not to the AHI. 14 
Evidence
also suggested that nocturnal hypoxemia appeared to be more robust to predict outcomes in stable chronic heart failure compared with AHI. 11, 15 However, it is unclear whether nocturnal hypoxemia is better than AHI in predicting the outcomes in ADHF. Therefore, in the present study, we aimed to compare AHI and several parameters of nocturnal hypoxemia in evaluating the prognosis in hospitalized heart failure patients.
| METHODS

| Patients
This single-center, prospective, observational study was performed in Heart Failure Center, Fuwai Hospital. From January 2015 to December 2017, patients with ADHF were consecutively enrolled, including both new-onset heart failure and decompensation of chronic heart failure. ADHF was diagnosed based on symptoms/signs of fluid overload and/or hypoperfusion, and appropriate additional investigations such as chest X-ray, electrocardiogram, N-terminal pro-brain natriuretic peptide (NT-proBNP), and echocardiography according to the European Society of Cardiology Guidelines. 16 The exclusive criteria were as follows: age <18 or >80 years; any coronary event within the previous 3 months or at the time of enrollment, namely, acute coronary syndrome (ACS), percutaneous coronary invention, coronary artery bypass grafts; implantation of pacemaker, implantable cardioverter defibrillation (ICD), or cardiac resynchronization therapy within the previous 3 months; heart valvular surgeries within the previous 3 months; stroke within the previous 6 months; dialysis; chronic obstructive pulmonary disease; acute myocarditis or infective endocarditis; significant uncorrected valvular heart disease; malignancy; pregnancy; diagnosed sleep apnea, or previously receiving any type of positive pressure ventilation or oxygen therapy. Patients were also excluded if they were admitted to hospital for cardiovascular interventions and surgeries. The study protocol conformed to the Declaration of Helsinki and was approved by the institutional review board of Fuwai Hospital. Individual informed consents were signed.
| Sleep study
Patients received sleep studies by means of Apnealink Plus (Resmed, Ltd, Martinsried, Germany) from 22:00 to 6:00 after an initial improvement of heart failure during the hospitalization period by intensive therapy. Patients undergoing sleep study were requested to relieve from edema and lie in a supine position without dyspnea under room air.
Sleep studies were not done on patients who were hemodynamically unstable, had nocturnal dyspnea, needed oxygen supplement or ventilation. Nasal airflow amplitude and oxygen saturation were measured by a nasal flow pressure cannula and a finger pulse oximeter, respectively.
The recorded data were analyzed by two-step method. First, the data were analyzed automatically by software, Apnealink Version 10.20. Then the recordings were manually reanalyzed by a sleep specialist who was blinded to the clinical status of patients. In recordings, only time periods with both sufficient airflow and saturation signals were considered valid recording time. We only took account those sleep studies with a minimum 4-hour valid recording time. Apnea was defined as breathing amplitude decreased by ≥90% for ≥10 seconds. Hypopnea was defined as breathing amplitude decreased by ≥30% lasting for ≥10 seconds, accompanied by a ≥3% drop in oxygen saturation. 17 AHI was defined as the total number of apneas and hypopneas per hour. Sleep apnea was defined as AHI ≥15/h. Oxygen desaturation index (ODI) was defined as the total number of desaturation events where oxygen saturation decreased by ≥3% per hour. The mean saturation (meanSO 2 ), the minimal saturation (minSO 2 ), and T90% during sleep were also recorded. 
| Blood samples and echocardiography
| Follow-up and endpoint
The enrolled patients were systematically followed up every 3 months by outpatient reviews or telephone calls after discharge until December 31, 2018. Follow-up was terminated when death, heart transplantation, or implantation of left ventricular assist device (LVAD) occurred. The endpoint was defined as the first event of death from any cause, heart transplantation, LVAD implantation, unplanned hospitalization for worsening heart failure, ACS, significant arrhythmias, and stroke. Significant arrhythmia event was defined as sustained ventricular tachycardia, ventricular fibrillation of asystole. Information of the adverse events was obtained from the medical records for those patients who were followed up at our hospital. For those patients who were not followed up at our hospital, detailed information was obtained by telephone calls with patients' families and local medical institutions they were admitted to if necessary. Data regarding the adverse events were collected and determined by two blinded cardiologists. 
| Statistical analysis
| RESULTS
A total of 420 patients who met the predefined inclusion/exclusion criteria were followed up systematically after discharge. Follow-up Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio; MAP, mean atrial blood pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; T90%, the percentage of time with oxygen saturation below 90%. more diuretics. There were no differences of AHI and AHI categories between patients with and without the endpoint. T90% was significantly higher in patients with the endpoint ( Table 1) .
The Kaplan-Meier analysis showed the incidence of the endpoint did not differ between AHI categories (≥15/h vs <15/h: 52.4% vs 44.6%, χ 2 = 0.862, log rank P = .353; Figure 2A ), ODI categories (≥19.0/h vs < 19.0/h, 50.8% vs 46.0%, χ 2 = 0.461, log rank P = .497), meanSO 2 categories (<95.0% vs ≥95.0%, 51.1% vs 45.9%, χ 2 = 0.630, log rank P = .428), or minSO 2 categories (<79.0% vs ≥79.0%, 54.7% vs 42.2%, χ 2 = 2.933, log rank P = .087). Patients with T90% ≥3.6% had a significantly higher incidence of the endpoint than those with T90% <3.6% (54.5% vs 42.4%, χ 2 = 5.137, log rank P = .023; Figure 2B ).
Univariate Cox analysis showed T90% was associated with the showed significant association with the endpoint (Table S3 ). Univariate analysis also showed that age, BMI, hypertension, atrial fibrillation, renal dysfunction, NYHA class (III/IV), NT-proBNP, LVEF, MAP, ACEI/ARB, and diuretics were associated with the endpoint with a statistical significance of P < .10. The above variables along with sleep study parameters were included in multivariate Cox analysis (Table S4 ).
In stepwise multivariate Cox regression analysis, the effect of T90% on the prognosis was still statistically significant (HR 1.008, 95%CI 1.001-1.016, P = .033). The risk of the endpoint increased by 40% in patients with T90% ≥3.6% (HR 1.408, 95%CI 1.030-1.925, P = .032; Table 2 ). The results of multivariate analysis also demonstrated that the risk of the endpoint was associated with the level of minSO 2 (HR 0.985, 95%CI 0.973-0.997, P = .017), the risk of the endpoint was 39.5% higher in patients with minSO 2 <79.0% than those with minSO 2 ≥79.0% (HR 1.395 95%CI 1.038-1.876, P = .028; 
| DISCUSSION
In this study, we compared the impact of AHI and parameters of nocturnal hypoxemia on the prognosis in patients with decompensated heart failure. The results showed that the nocturnal hypoxemia, calculated by the percentage of time with saturation below 90% (T90%), rather than the frequency of apneas and hypopneas, was an independent predictor of adverse outcomes in decompensated heart failure.
The proportion of sleep apnea (AHI ≥15/h) in the present study was smaller than previous studies. 1, 2 Compared with those studies, BMI in the present study was lower. As AHI is correlated with BMI, 18, 19 the relatively lower BMI might partly explain the lower prev- AHI might not be the best metric to determine the severity of sleep apnea in heart failure. As mainly reflecting the frequency of apneas and hypopneas during sleep on its own definition, AHI does not consider the durations of apneas and hypopneas. As a consequence, AHI cannot differentiate between apneas and hypopneas with the same number but different durations. Moreover, the lengths of apneas and hypopneas are dependent on cardiac function. 22 The greater the extent of cardiac dysfunction, the longer apneas and hypopneas will be. As a result, the total number of apneas and hypopneas is potentially limited in heart failure and the severity of sleep apnea, determined by AHI, is consequently underestimated. Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CI, confidence interval; HR, hazard raito; MAP, mean atrial blood pressure; MinSO 2 , the minimal oxygen saturation; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association.
The result of our study demonstrated that some parameters representative of nocturnal hypoxemia (ie, T90% and minSO 2 ) were better than AHI in predicting adverse outcomes in ADHF, which was consistent with some previous studies in stable chronic heart failure.
Oldenburg et al 11 showed significant association with the prognosis. 15 In addition, minSO 2 was also demonstrated a more robust association with fatal or resuscitated sudden cardiac death than AHI. 23 These findings suggested that nocturnal hypoxemia might better represent the detrimental effects of sleep apnea than the frequency of apneas and hypopneas in heart failure. It was reported that T90%, rather than AHI, predicted the elevations in brain natriuretic peptide, 14 indicating nocturnal hypoxemia might be an important factor underlying the impact of sleep apnea on acute hemodynamic stress in heart failure. Another study found that cardiac norepinephrine spillover was correlated with a reduced oxygen saturation, but not with the AHI, 24 indicating increased sympathetic activity was more associated with nocturnal hypoxemia. Overall, nocturnal hypoxemia might be a better measure representative of adverse effects of sleep apnea than AHI, explaining why it was better than the frequency of apneas and hypopneas in predicting the prognosis in ADHF. Additionally, AHI value does not accurately reflect the severity of nocturnal hypoxemia. T90 values of zero or close to zero were frequently observed in combination with a wide range of AHI values, 11 34 A randomized controlled trial has been registered to assess the efficacy of an oral appliance for sleep-disordered breathing and cardiac function in patients with heart failure. 35 These novel therapeutic approaches might provide new insight into treatment of sleep apnea.
We acknowledged there were several limitations in the present study. First, the relatively small sample size and short follow-up might decrease the generalizability of the prognostic value of AHI and the parameters of nocturnal hypoxemia. Second, we used a portable screening device rather than the full polysomnography to determine AHI. Theoretically, AHI obtained from the portable device is probably underestimated because it calculates the recording time rather than the actual sleep time and does not take arousals into consideration.
Third, pulmonary congestion might be a potential factor to influence blood oxygen saturation. In the study, patients received intensive therapy of heart failure before sleep studies. All patients undergoing sleep studies were requested to lie in a supine position without dyspnea under room air and relieve from edema. Although we did not perform specific imaging examination to assess pulmonary edema at the time of sleep studies, clinical status of patients indicated that pulmonary edema was alleviated. Forth, we did not consider the influence of treatment for sleep apnea on the prognosis during the followup. We excluded the effect of ventilation therapy from the analysis because the percentage of patients treated with nocturnal ventilation was quite small in the present study. The low level of awareness of sleep apnea and the high expenditure of ventilator might explain the low percentage of ventilation usage to some extent. Besides, it remains controversial over the prognostic effect of positive airway pressure ventilation in sleep apnea. 29, 36, 37 Considering the results of the study, further research is required to examine the prognostic influences of oxygen therapy in patients with heart failure and sleep apnea.
| CONCLUSION
This study demonstrated that nocturnal hypoxemia was more predictive of adverse outcomes in decompensated heart failure than the fre- 
